Effects of Telmisartan on the Expression of NADPH Oxidase in the Pancreatic Islet of Db/db Mice

邵加庆,顾萍,杜宏,卢斌,李洁,彭丽,王燕燕,赵明,王坚

DOI: https://doi.org/10.3969/j.issn.1008-8199.2010.07.002

2010-01-01

Abstract:Objective Epidemiological studies have suggested that the angiotensin Ⅱ type 1 receptor blocker (ARB) may reduce the risk of type 2 diabetes,but its mechanisms remain to be elucidated.The aim of this study was to explore the effects of telmisartan on the intra-islet levels of NADPH oxidase in db/db mice.Methods Twenty-two db/db mice,8 weeks of age,were equally randomized to two groups to receive placebo and telmisartan at 5 mg/kg daily via gavage.Another 11 age-matched db/misty mice were treated with placebo as non-diabetic controls.Body weight and random blood glucose were measured every week.The intraperitoneal glucose tolerance test and immunohistochemical staining of NADPH oxidase subunits gp91phox and p22phox were performed after 6 weeks′ treatment.Results Telmisartan treatment improved glucose tolerance,insulin secretion and insulin sensitivity,and remarkably decreased the staining intensity of the oxidative stress sources including p22phox and gp91phox in islets.Conclusion Telmisartan treatment can decrease the expression level of NADPH oxidase in β-cells,reduce oxidative stress sources,and thus protect β-cells.